2022
Imaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2021
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood 2021, 138: 1494. DOI: 10.1182/blood-2021-151978.Peer-Reviewed Original ResearchLeukemia-free survivalEntity's Board of DirectorsTN diseaseMedian OSOverall survivalTN patientsConstitutional symptomsMyeloproliferative neoplasmsNon-TN patientsBCR-ABL1 negative myeloproliferative neoplasmsMedian leukemia-free survivalPresence of constitutional symptomsResponse to ruxolitinibTransformation to AMLHigher-risk diseaseNegative myeloproliferative neoplasmsAggressive clinical courseDiagnosis of MFKaplan-Meier methodShorter survival rateMoffitt Cancer CenterAdvisory CommitteeBlood cell productionCTI BioPharmaTN cohortClinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics
Aguirre L, Jain A, Ball S, Al Ali N, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Kuykendall A, Komrokji R. Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics. Blood 2021, 138: 2571. DOI: 10.1182/blood-2021-152026.Peer-Reviewed Original ResearchMonths of diagnosisPrimary myelofibrosisActive surveillanceMedian OSMyeloproliferative neoplasmsBCR-ABL1 negative myeloproliferative neoplasmsNegative myeloproliferative neoplasmsTriple-negative diseasePercentage of circulating blastsPrognostic scoring systemDiagnosis of MFRates of anemiaLower-risk patientsMoffitt Cancer CenterDisease-related symptomsKaryotypic riskSymptomatic splenomegalyMarrow myeloblastsTransfusion dependenceConstitutional symptomsJAK2 mutationBCR-ABL1No significant differenceAggressive subtypeBaseline characteristics
2020
Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report
Aguirre L, Schwartz I, Chapman J, Larsen M, Alencar A. Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report. Journal Of Medical Case Reports 2020, 14: 169. PMID: 32979930, PMCID: PMC7520028, DOI: 10.1186/s13256-020-02460-3.Peer-Reviewed Original ResearchConceptsLangerhans cell histiocytosisLangerhans cell sarcomaCell histiocytosisCell sarcomaPoor prognosisLow dose of cytarabineAcute myeloid leukemia inductionMultisystem Langerhans cell histiocytosisAdult Langerhans cell histiocytosisRisk organ involvementDoses of cytarabineProliferation of dendritic cellsAcute monoblastic leukemiaSarcomatoid featuresClonal disorderComplex karyotypeRare entityCase presentationWeRare neoplasmsConstitutional symptomsEarly satietyCell tumorsDendritic cellsOrgan involvementAggressive featuresInterferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.Peer-Reviewed Original ResearchConceptsOverall response rateTreatment of myelofibrosisPEG-IFNMF patientsResponse rateHematologic responseSystematic reviewFormulations of interferonPartial hematologic responseCochrane Central RegisterComplete hematologic responseRisk of progressionRole of interferonAcute myeloid leukemiaPhiladelphia chromosome-negative myeloproliferative neoplasmsRandom-effects modelBone marrow failureWeb of ScienceTreatment discontinuationCentral RegisterConstitutional symptomsHematologic improvementInterferon therapyAdverse eventsComplete response
2019
Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis
Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia 2019, 19: 593-597. PMID: 31262666, PMCID: PMC6814397, DOI: 10.1016/j.clml.2019.05.009.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionSecondary myelofibrosisOverall survivalMF patientsPrimary myelofibrosisSingle-center retrospective chart reviewGroup 5 pulmonary hypertensionImpact of PHInfluence of PHPresence of PHChronic obstructive pulmonary diseaseRetrospective patient databaseIntermediate-risk patientsRetrospective chart reviewObstructive pulmonary diseaseBone marrow fibrosisPathogenesis of myelofibrosisMF cohortRoutine echoConstitutional symptomsChart reviewRisk patientsPulmonary diseaseTransthoracic echoMarrow fibrosis
2018
A rare presentation of pulmonary sarcoidosis as a solitary lung mass: a case report
Kelleher DW, Yaggi M, Homer R, Herzog EL, Ryu C. A rare presentation of pulmonary sarcoidosis as a solitary lung mass: a case report. Journal Of Medical Case Reports 2018, 12: 94. PMID: 29650028, PMCID: PMC5897926, DOI: 10.1186/s13256-018-1632-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSolitary lung massPulmonary sarcoidosisBroad differential diagnosisLung massConstitutional symptomsHilar lymphadenopathyRadiographic featuresDifferential diagnosisLarge left lower lobe massStage II pulmonary sarcoidosisComputed tomography-guided biopsyType 2 diabetes mellitusHigh-dose prednisoneLower lobe massTomographic scan findingsMonths of therapyUnintentional weight lossEvidence of malignancySarcoid-like reactionTomography-guided biopsyShortness of breathNon-necrotizing granulomasChronic granulomatous diseaseAfrican American womenOccult malignancyMinocycline-Induced Polyarteritis Nodosa Presenting With Testicular Pain: A Case Report and Selected Review of the Literature
Findlay B, Kwon Y, Sterling J, Fatima A, Moorthy L, Halko G, Sadimin E, Barone J. Minocycline-Induced Polyarteritis Nodosa Presenting With Testicular Pain: A Case Report and Selected Review of the Literature. World Journal Of Nephrology And Urology 2018, 7: 32-37. DOI: 10.14740/wjnu337w.Peer-Reviewed Original ResearchTesticular painPolyarteritis nodosaUnilateral testicular painSystemic polyarteritis nodosaSystemic necrotizing vasculitisAccurate tissue diagnosisFocal necrotizing vasculitisFollow-up visitPrevention of complicationsBiopsy demonstratingTesticular manifestationConstitutional symptomsTissue diagnosisPrompt diagnosisNecrotizing vasculitisCase reportAcne treatmentAneurysm formationOptimal managementPainTesticularDiagnosisRheumatologistsVasculitisUrologists
2017
Management of myelofibrosis: JAK inhibition and beyond
Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Review Of Hematology 2017, 10: 459-477. PMID: 28395559, DOI: 10.1080/17474086.2017.1317590.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow fibrosisMarrow fibrosisAbnormal cytokine expressionClinical trial evidenceJAK2 V617F allele burdenErythropoiesis stimulating agentsNovel therapeutic optionsAnti-fibrosis agentsV617F allele burdenJAK2 inhibitor ruxolitinibNovel therapeutic agentsJAK2 V617F mutationConstitutional symptomsCytoreductive drugsSymptom burdenImmunomodulatory drugsSurvival improvementJAK1/2 inhibitorMF patientsTherapeutic optionsTrial evidenceCytokine expressionExtramedullary hematopoiesisPrognostic assessmentRuxolitinib monotherapy
2015
EGFR-directed antibodies increase the risk of severe infection in cancer patients
Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSevere infectionsMonoclonal antibodiesRole of EGFRDose modification strategiesMonoclonal antibody treatmentClinical trial designRisk of infectionPractice of oncologyGrowth factor receptorConstitutional symptomsAntibody treatmentHypersensitivity reactionsCancer patientsRadiation therapyTrial designSolid tumorsInfection riskInfectionFactor receptorAntibodiesFurther studiesPatientsRiskRelated articles
2011
Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. Clinical Cancer Research 2011, 17: 5748-5754. PMID: 21747120, PMCID: PMC3725971, DOI: 10.1158/1078-0432.ccr-11-0556.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingDacarbazineDNA DamageDNA Mismatch RepairFemaleHumansMaleMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinMycosis FungoidesNuclear ProteinsO(6)-Methylguanine-DNA MethyltransferaseSezary SyndromeTemozolomideTreatment OutcomeConceptsMycosis fungoides/Sézary syndromeMulticenter phase II trialPhase II trialMF/SSMethylguanine-DNA methyltransferaseMutL homolog 1II trialSézary syndromeMedian disease-free survivalMismatch repair protein expressionGrade 3 thrombocytopeniaMedian overall survivalDisease-free survivalEfficacy of temozolomideRepair protein expressionProtein expression levelsOral derivativeComplete remissionConstitutional symptomsFrequent toxicitiesGastrointestinal symptomsHematologic toxicityPartial remissionClinical responseOverall survival
2009
Noninfectious Ascending Aortitis: A Case Series of 64 Patients
Liang KP, Chowdhary VR, Michet CJ, Miller DV, Sundt TM, Connolly HM, Crowson CS, Matteson EL, Warrington KJ. Noninfectious Ascending Aortitis: A Case Series of 64 Patients. The Journal Of Rheumatology 2009, 36: 2290-2297. PMID: 19648309, DOI: 10.3899/jrheum.090081.Peer-Reviewed Original ResearchConceptsGiant cell arteritisAscending aortitisClinical presentationPreoperative erythrocyte sedimentation rateAortic aneurysm resectionMedian followup timePolymyalgia rheumatica symptomsRetrospective medical recordsErythrocyte sedimentation rateMajor aortic branchesAbsence of historyAdditional vascular abnormalitiesAneurysm resectionNoninfectious aortitisRheumatologic historyConstitutional symptomsCell arteritisImaging abnormalitiesInitial presentationSuch patientsCase seriesClinicopathologic featuresFollowup timeAbdominal aneurysmClinical entity
2005
Comparison of Histopathologic Features, Clinical Symptoms, and Erythrocyte Sedimentation Rates in Biopsy-Positive Temporal Arteritis
Diaz VA, DeBroff BM, Sinard J. Comparison of Histopathologic Features, Clinical Symptoms, and Erythrocyte Sedimentation Rates in Biopsy-Positive Temporal Arteritis. Ophthalmology 2005, 112: 1293-1298. PMID: 15921755, DOI: 10.1016/j.ophtha.2005.02.016.Peer-Reviewed Original ResearchConceptsErythrocyte sedimentation rateTemporal arteritisClinical symptomsBiopsy specimensConstitutional symptomsBilateral biopsiesClinical presentationHistopathologic stageESR valuesVisual symptomsBilateral biopsy specimensPatient's clinical symptomsRetrospective case seriesTemporal artery biopsyMean ESR valuesScalp painSuperficial painSedimentation rateArtery biopsyPatient chartsCase seriesUnilateral biopsyHistopathologic featuresPathologic gradePatient population
2003
Interferon-Induced Sarcoidosis
Rubinowitz AN, Naidich DP, Alinsonorin C. Interferon-Induced Sarcoidosis. Journal Of Computer Assisted Tomography 2003, 27: 279-283. PMID: 12703026, DOI: 10.1097/00004728-200303000-00030.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionNonspecific constitutional symptomsC virus infectionHepatitis C infectionCases of sarcoidosisC infectionConstitutional symptomsInterferon therapyPulmonary involvementImportant complicationNonmalignant diseasesVirus infectionInvasive proceduresSide effectsTherapySarcoidosisPatientsInfectionComplicationsInterferonSymptomsDiseasePhysiciansUncommon
1998
Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey.
Coffin C, Humphrey P, Dehner L. Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Seminars In Diagnostic Pathology 1998, 15: 85-101. PMID: 9606801.Peer-Reviewed Original ResearchConceptsInflammatory myofibroblastic tumorExtrapulmonary sitesAberrant inflammatory responseSoft tissue mesenchymal tumorsLow malignant potentialEpstein-Barr virusSpindle cell sarcomaSpindle cell neoplasmConstitutional symptomsInflammatory hypothesisInflammatory pseudotumorSurgical resectionInflammatory natureLocal recurrenceMyofibroblastic tumorPrognostic categoriesVascular invasionCell sarcomaPathological featuresMalignant potentialInflammatory processPathological diagnosisInflammatory responseCell neoplasmsEmbryonal rhabdomyosarcoma
1997
Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G, Galai N, Pezzotti P, Vlahov D, Graham N, Viale P, Angarano G. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study. Antiviral Therapy 1997, 2: 167-74. PMID: 11322271.Peer-Reviewed Original ResearchConceptsCD4 cell countInitiation of treatmentZidovudine monotherapyP24 antigenaemiaCell countConstitutional symptomsHIV seroconvertersRisk groupsCopies/Human immunodeficiency virus seroconvertersPlasma RNA viral loadHIV RNA copiesCD4 cell declineRNA viral loadStart of therapyMarker of responseAntigen-positive individualsAdditional predictive informationIndicator of responseStandard survival methodsTerms of progressionAntiretroviral therapyViral loadAntigen levelsDisease progression
1996
A Middle-Aged Woman with Back and Flank Pain
Cruz D, Perazella M, Mahnensmith R. A Middle-Aged Woman with Back and Flank Pain. Hospital Practice 1996, 31: 193-209. PMID: 8814129, DOI: 10.1080/21548331.1996.11443354.Peer-Reviewed Original ResearchConceptsMiddle-aged womenFlank painFrank renal failureAbnormal liver enzymesCareful preoperative evaluationUrinary tract infectionExtent of inflammationLipid-laden macrophagesRadiologic imaging techniquesChronic pyelonephritisConstitutional symptomsFlank massRenal failureTract infectionsPreoperative evaluationDraining sinusMild azotemiaXanthogranulomatous pyelonephritisXanthoma cellsSubsequent careLiver enzymesAdequate exposureUncommon variantCT scanSurgical planning
1992
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein R, Davenny K, Friedland G. Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 327: 1697-1703. PMID: 1359411, DOI: 10.1056/nejm199212103272401.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCandidiasis, OralCD4-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMaleMultivariate AnalysisNew York CityProportional Hazards ModelsProspective StudiesRacial GroupsSubstance Abuse, IntravenousZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSInjection drug usersBacterial infectionsDisease progressionOral candidiasisVirus infectionSite primary medical careMultiple constitutional symptomsPyogenic bacterial infectionsHIV-seropositive patientsPercentage of CD4Cohort of patientsDiagnosis of AIDSMethadone treatment programsProportional hazards regressionProduct-limit survival analysisIncidence of AIDSPrimary medical careRate of progressionRisk of AIDSSeronegative patientsConstitutional symptomsSeropositive patientsPeritoneal coccidioidomycosis associated with human immunodeficiency virus infection
Jamidar P, Campbell D, Fishback J, Klotz S. Peritoneal coccidioidomycosis associated with human immunodeficiency virus infection. Gastroenterology 1992, 102: 1054-1058. PMID: 1531643, DOI: 10.1016/0016-5085(92)90197-7.Peer-Reviewed Original ResearchConceptsImmunodeficiency syndrome-defining illnessPeritoneal coccidioidomycosisDramatic responseLow serum-ascites albumin gradientHuman immunodeficiency virus-infected patientsHuman immunodeficiency virus (HIV) infectionSerum-ascites albumin gradientImmunodeficiency virus infectionResolution of ascitesSystemic antifungal therapyVirus-infected patientsHuman immunodeficiency virusFirst caseCoccidioidal peritonitisUnexplained ascitesConstitutional symptomsPrompt therapyPeritoneal implantsImmunodeficiency virusAntifungal therapyTimely diagnosisVirus infectionAlbumin gradientCoccidioidomycosisAscites
1991
HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users.
Royal W, Updike M, Seines O, Proctor T, Nance-Sproson L, Solomon L, Vlahov D, Cornblath D, McArthur J. HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users. Neurology 1991, 41: 1905-10. PMID: 1745346, DOI: 10.1212/wnl.41.12.1905.Peer-Reviewed Original ResearchConceptsHIV-1 serostatusIntravenous drug usersNeurologic abnormalitiesDrug usersSeronegative intravenous drug usersCD4 cell countHIV-seropositive subjectsHIV-1 infectionNervous system abnormalitiesConstitutional symptomsElectrophysiologic evaluationSeropositive participantsSeropositive subjectsElectrophysiologic abnormalitiesHIV infectionStudy cohortNeurologic diseaseSystem abnormalitiesHomosexual menCell countSerologic groupsCohortAbnormalitiesClear associationNeuropsychological tests
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply